Efficacy and Safety of Brentuximab Vedotin with ABVD or AVD in Newly Diagnosed Advanced HL


Efficacy and Safety of Brentuximab Vedotin with ABVD or AVD in Newly Diagnosed Advanced HL
Slides from a presentation at ASH 2011 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/11/12)

Younes A et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Proc ASH 2011;Abstract 955.

Dr Moskowitz is Clinical Director in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.